Printer Friendly

CAMBRIDGE NEUROSCIENCE BEGINS MULTI-CENTER CLINICAL TRIALS OF NEW PSYCHIATRIC PRODUCT

 CAMBRIDGE NEUROSCIENCE BEGINS MULTI-CENTER CLINICAL TRIALS OF
 NEW PSYCHIATRIC PRODUCT
 CAMBRIDGE, Mass., March 25 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) announced today that multi-center clinical trials of its new psychiatric drug, ECTAPRAM(tm) (pramiracetam) have begun. ECTAPRAM will be studied as an adjunct to electroconvulsive therapy (ECT) to enhance the anti-depressant effects of the therapy and to reduce unwanted side effects, such as confusion and memory loss. The trial is double blind, placebo controlled and will involve between 10 and 20 treatment centers in the United States, with an enrollment of over 100 patients.
 "We have achieved a significant milestone with the initiation of these trials," stated Dr. Elkan R. Gamzu, president and chief operating officer of Cambridge NeuroScience. "We are on schedule in bringing ECTAPRAM to clinical trials in severely depressed patients undergoing ECT. About 100,000 courses of ECT are administered annually," he added, "and some clinicians believe that if the unwanted side effects of ECT could be eliminated, such treatment could be utilized more widely. ECTAPRAM represents an excellent niche product for Cambridge NeuroScience that should generate attractive revenues."
 Based on discussions with the Food and Drug Administration, the company has decided to run two consecutive studies. The first study could provide evidence of efficacy. Confirmation of the data could complete the New Drug Application efficacy requirements. Cambridge NeuroScience was recently granted Orphan Drug Status for ECTAPRAM, giving it exclusivity to market the drug in the United States for seven years following regulatory approval. The company licensed development and marketing rights to the drug from Warner-Lambert Company in 1991.
 Cambridge NeuroScience is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceutical products to treat a variety of severe neurological and psychiatric disorders. The company's product development efforts are focused in three areas: neuroprotective compounds for treatment of acute neurological disorders such as stroke and traumatic brain injury; novel antipsychotic compounds for the treatment of mental illnesses such as schizophrenia; and growth factors for the treatment of neurodegenerative diseases such as diabetic peripheral neuropathies and amyotrophic lateral sclerosis (Lou Gehrig's disease).
 -0- 3/25/92
 /CONTACT: John T. Smith of Cambridge NeuroScience, 617-225-0600, ext. 151/
 (CNSI) CO: Cambridge NeuroScience, Inc. ST: Massachusetts IN: MTC SU:


SH -- NE003 -- 1431 03/25/92 10:20 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 25, 1992
Words:380
Previous Article:ROCHESTER GAS AND ELECTRIC BOND FINANCING
Next Article:CENTRAL PENNSYLVANIA FINANCIAL ANNOUNCES DIVIDEND
Topics:


Related Articles
CAMBRIDGE NEUROSCIENCE BEGINS HUMAN CLINICAL TRIALS OF NOVEL ANTI-STROKE COMPOUND
PRECLINICAL DATA ON NEUROPROTECTIVE COMPOUND FROM CAMBRIDGE NEUROSCIENCE PUBLISHED IN "NEUROLOGY"
CAMBRIDGE NEUROSCIENCE DISCONTINUES ECTAPRAM, AN IN-LICENSED ORPHAN DRUG PRODUCT, AND REDIRECTS RESOURCES TO STROKE AND GROWTH FACTOR PROGRAMS
CAMBRIDGE NEUROSCIENCE INITIATES CLINICAL TRIALS OF CERESTAT FOR TRAUMATIC BRAIN INJURY; FIRST U.S. TBI TRIAL BEGINS AT HERMANN HOSPITAL
CAMBRIDGE NEUROSCIENCE EXPANDS CLINICAL STUDIES OF CERESTAT(TM) IN STROKE PATIENTS
ADDITIONAL SAFETY RESULTS PRESENTED FOR CAMBRIDGE NEUROSCIENCE'S CERESTAT(TM)
CAMBRIDGE NEUROSCIENCE BEGINS MULTINATIONAL DOSE-FINDING STUDY OF CERESTAT(TM) IN STROKE PATIENTS
CAMBRIDGE NEUROSCIENCE COMPLETES ENROLLMENT FOR PHASE II DOSE RESPONSE STUDY OF CERESTAT(R) IN STROKE PATIENTS
CLINICAL DATA SUPPORTING CERESTAT(R) IN STROKE PATIENTS REPORTED AT AMERICAN HEART ASSOCIATION MEETING
CAMBRIDGE NEUROSCIENCE INITIATES PHASE III STUDY OF CERESTAT(R) IN PATIENTS WITH TRAUMATIC BRAIN INJURY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters